← Human Trials & Peer-Reviewed Studies
Combined Probiotic Lactiplantibacillus plantarum ECGC 13110402 and Plant Sterol Supplement May Improve Lipids and Gut Microbiota in Coeliac Adults: A Randomised, Placebo-Controlled Pilot Human Intervention Study.
Plain-language guide to PMID 42197276 (2026): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 42197276
- Journal
- Molecules (Basel, Switzerland)
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Costabile A et al. (12 authors)
- DOI
- 10.3390/molecules31101722
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
This 9-week, double-blind, placebo-controlled, randomised pilot study investigated the effects of a combined supplement containing probiotic Lactiplantibacillus plantarum ECGC 13110402 and plant sterols and stanols, on cardiometabolic biomarkers and gut microbiota diversity and composition in adults with CeD and hypercholesterolaemia.
Blood lipid profiles and vitamin D concentrations were analysed, and gut microbiota was profiled via 16S rRNA amplicon sequencing.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Copper (Supplement), giving a reference point.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
What Was Measured
Topics PubMed links to this paper include Probiotics, Pilot Projects, Celiac Disease, Phytosterols, Dietary Supplements, Lipids and Gastrointestinal Microbiome.
The authors tagged it with the keywords Lactiplantibacillus plantarum ECGC 13110402, cardiometabolic health, coeliac disease, dyslipidemia, gut microbiota and lipid profile.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2026 (Molecules (Basel, Switzerland)), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.